People · Operator
Named in public records as an officer, director or promoter · active 2011–2011 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Enobia Pharma Corp | — | Biotechnology | Series C | $100.0M | $819.2M | 2011 |
David L. Bonita at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David L. Bonita on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jonathan Silverstein | 1 | 10 |
| David Bonita | 1 | 6 |
| Thomas Schuetz | 1 | 4 |
| Eric L. Trachtenberg | 1 | 4 |
| Jeffrey Mack | 1 | 3 |
| Richard Meadows | 1 | 2 |
| Robert Heft | 1 | 1 |
| Frederic Price | 1 | 1 |
| Luc Cournoyer | 1 | 1 |
| Luc Mainville | 1 | 1 |
| Thomas L. Schuetz | 1 | 1 |
| Luc L. Mainville | 1 | 1 |
| Richard L. Meadows | 1 | 1 |
| Frederic L. Price | 1 | 1 |
| Jonathan L. Silverstein | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.